AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

$17.24 +0.51 (+3.05 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$17.24
Today's Range$16.67 - $17.25
52-Week Range$14.80 - $18.85
Volume155,499 shs
Average Volume237,924 shs
Market Capitalization$652.80 million
P/E Ratio-63.85
Dividend YieldN/A
Beta0.98

About AngioDynamics (NASDAQ:ANGO)

AngioDynamics logoAngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

Receive ANGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Supplies
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:ANGO
CUSIP03475V10
Phone+1-518-7981215

Debt

Debt-to-Equity Ratio0.17%
Current Ratio2.56%
Quick Ratio1.65%

Price-To-Earnings

Trailing P/E Ratio-63.8518518518518
Forward P/E Ratio23.94
P/E Growth1.55

Sales & Book Value

Annual Sales$349.64 million
Price / Sales1.81
Cash Flow$1.45 per share
Price / Cash11.87
Book Value$14.00 per share
Price / Book1.23

Profitability

Trailing EPS($0.27)
Net Income$5 million
Net Margins-2.27%
Return on Equity4.63%
Return on Assets3.43%

Miscellaneous

Employees1,250
Outstanding Shares36,740,000

AngioDynamics (NASDAQ:ANGO) Frequently Asked Questions

What is AngioDynamics' stock symbol?

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) announced its earnings results on Thursday, January, 4th. The medical instruments supplier reported $0.16 EPS for the quarter, hitting the Zacks' consensus estimate of $0.16. The medical instruments supplier earned $86.70 million during the quarter, compared to analysts' expectations of $88.15 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. The company's quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.19 EPS. View AngioDynamics' Earnings History.

When will AngioDynamics make its next earnings announcement?

AngioDynamics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 28th 2018. View Earnings Estimates for AngioDynamics.

Where is AngioDynamics' stock going? Where will AngioDynamics' stock price be in 2018?

5 Wall Street analysts have issued twelve-month price targets for AngioDynamics' shares. Their forecasts range from $16.00 to $21.00. On average, they anticipate AngioDynamics' stock price to reach $18.50 in the next year. View Analyst Ratings for AngioDynamics.

What are Wall Street analysts saying about AngioDynamics stock?

Here are some recent quotes from research analysts about AngioDynamics stock:

  • 1. According to Zacks Investment Research, "Despite trading below the broader industry in the last year, market’s solid response to Solero platform, especially within the Microwave Ablation space, is likely to boost AngioDynamics. The company has been offering a broad spectrum of products which has helped widen its commercial opportunities. AngioDynamics is also a leading player in the thrombolytic catheters space. The company boasts highly unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio. On the flipside, the company’s Peripheral Vascular business segment witnessed a downside scenario. The company also had a high outstanding debt level at the end of the last quarter. AngioDynamics’ higher debts impose certain operating and financial restrictions which limit the company’s execution of the company’s core business strategies. The company also recalled the Acculis Microwave Tissue Ablation System recently." (1/26/2018)
  • 2. Cantor Fitzgerald analysts commented, "F3Q17 Result Summary. F3Q17 total revenues of $85.6M (down 2.0% y/y), was $3.2M below our estimate of $88.8M and $2.7M below FactSet consensus of $88.3M." (3/30/2017)

Who are some of AngioDynamics' key competitors?

Who are AngioDynamics' key executives?

AngioDynamics' management team includes the folowing people:

  • Howard W. Donnelly, Independent Chairman of the Board (Age 56)
  • James C. Clemmer, President, Chief Executive Officer, Director (Age 53)
  • Michael C. Greiner, Chief Financial Officer, Executive Vice President, IR Contact Officer (Age 44)
  • Robert A. Simpson, Senior Vice President and General Manager, Peripheral Vascular (Age 45)
  • Heather J. Daniels-Cariveau, Senior Vice President of Human Resources (Age 43)
  • Gary Barrett, Senior Vice President,Quality and Regulatory Affairs (Age 47)
  • Chad T. Campbell, Senior Vice President and General Manager, Vascular Access (Age 46)
  • Benjamin Davis, Senior Vice President, Business Development (Age 52)
  • Barbara A. Kucharczyk, Senior Vice President-Global Operations (Age 44)
  • Warren G. Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs (Age 48)

Who owns AngioDynamics stock?

AngioDynamics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.88%), Broadfin Capital LLC (4.72%), Wells Fargo & Company MN (3.10%), Royce & Associates LP (2.99%), Fenimore Asset Management Inc. (1.62%) and Renaissance Technologies LLC (1.47%). Company insiders that own AngioDynamics stock include Avista Capital Partners Gp, Ll, Charles R Greiner, David F Burgstahler, James C Clemmer, Jan Stern Reed and Stephen A Trowbridge. View Institutional Ownership Trends for AngioDynamics.

Who sold AngioDynamics stock? Who is selling AngioDynamics stock?

AngioDynamics' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Bank of Montreal Can, Two Sigma Investments LP, Two Sigma Advisers LP, TIAA CREF Investment Management LLC, Broadfin Capital LLC, Lapides Asset Management LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for AngioDynamics.

Who bought AngioDynamics stock? Who is buying AngioDynamics stock?

AngioDynamics' stock was acquired by a variety of institutional investors in the last quarter, including Segall Bryant & Hamill LLC, Royce & Associates LP, Wells Fargo & Company MN, Renaissance Technologies LLC, BlackRock Inc., Thomson Horstmann & Bryant Inc., AXA and Deutsche Bank AG. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer and Jan Stern Reed. View Insider Buying and Selling for AngioDynamics.

How do I buy AngioDynamics stock?

Shares of AngioDynamics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AngioDynamics' stock price today?

One share of AngioDynamics stock can currently be purchased for approximately $17.24.

How big of a company is AngioDynamics?

AngioDynamics has a market capitalization of $652.80 million and generates $349.64 million in revenue each year. The medical instruments supplier earns $5 million in net income (profit) each year or ($0.27) on an earnings per share basis. AngioDynamics employs 1,250 workers across the globe.

How can I contact AngioDynamics?

AngioDynamics' mailing address is 14 Plaza Dr, LATHAM, NY 12110-2166, United States. The medical instruments supplier can be reached via phone at +1-518-7981215 or via email at [email protected]


MarketBeat Community Rating for AngioDynamics (ANGO)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about AngioDynamics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AngioDynamics (NASDAQ:ANGO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.202.402.40
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.50$18.50$18.50$18.40
Price Target Upside: 17.76% upside17.76% upside8.63% upside10.25% upside

AngioDynamics (NASDAQ:ANGO) Consensus Price Target History

Price Target History for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ:ANGO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018Craig HallumDowngradeBuy -> HoldHighView Rating Details
10/8/2017Canaccord GenuityReiterated RatingHold$17.00N/AView Rating Details
9/29/2017KeyCorpReiterated RatingHoldHighView Rating Details
7/19/2017BarclaysLower Price TargetEqual Weight$17.00 -> $16.00LowView Rating Details
7/4/2017Cantor FitzgeraldBoost Price TargetOverweight$20.00 -> $21.00LowView Rating Details
4/8/2016Piper Jaffray CompaniesInitiated CoverageNeutral$12.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

AngioDynamics (NASDAQ:ANGO) Earnings History and Estimates Chart

Earnings by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ ANGO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2018$0.19N/AView Earnings Details
1/4/2018Q2 2018$0.16$0.16$88.15 million$86.70 millionViewListenView Earnings Details
9/28/2017Q1 2018$0.16$0.12$86.12 million$85.40 millionViewN/AView Earnings Details
7/18/2017Q4 2017$0.16$0.19$90.72 million$86.90 millionViewN/AView Earnings Details
3/30/2017Q3 2017$0.15$0.19$88.29 million$85.60 millionViewN/AView Earnings Details
1/6/2017Q217$0.16$0.19$91.09 million$89.00 millionViewListenView Earnings Details
10/5/2016Q117$0.13$0.17$86.09 million$88.10 millionViewN/AView Earnings Details
7/13/2016Q416$0.16$0.19$88.64 million$93.40 millionViewListenView Earnings Details
4/7/2016Q3$0.14$0.15$85.43 million$87.40 millionViewListenView Earnings Details
1/7/2016Q216$0.14$0.14$88.67 million$89.20 millionViewN/AView Earnings Details
10/8/2015Q116$0.11$0.11$84.70 million$83.70 millionViewN/AView Earnings Details
7/16/2015Q415$0.14$0.14$91.67 million$90.90 millionViewListenView Earnings Details
4/9/2015Q315$0.15$0.12$88.69 million$86.60 millionViewN/AView Earnings Details
1/8/2015Q215$0.15$0.17$90.90 million$92.10 millionViewN/AView Earnings Details
10/9/2014Q115$0.11$0.16$85.35 million$87.30 millionViewListenView Earnings Details
7/23/2014Q414$0.12$0.18$93.65 million$94.07 millionViewListenView Earnings Details
4/9/2014Q314$0.09$0.16$86.85 million$88.20 millionViewListenView Earnings Details
1/9/2014Q2$0.07$0.14$87.54 million$88.60 millionViewListenView Earnings Details
10/10/2013Q114$0.03$0.04$82.54 million$83.60 millionViewN/AView Earnings Details
7/11/2013Q4 2013$0.06$0.07$86.43 million$90.00 millionViewN/AView Earnings Details
4/8/2013Q3 2013$0.05$0.08$81.70 million$81.60 millionViewN/AView Earnings Details
1/3/2013Q2 2013$0.09$0.10$87.40 million$87.00 millionViewN/AView Earnings Details
10/8/2012Q113$0.09$0.10$84.35 million$83.40 millionViewN/AView Earnings Details
7/12/2012$0.08$0.09ViewN/AView Earnings Details
4/4/2012$0.07$0.09ViewN/AView Earnings Details
1/5/2012$0.12$0.13ViewN/AView Earnings Details
10/6/2011$0.09$0.08ViewN/AView Earnings Details
7/14/2011$0.10$0.11ViewN/AView Earnings Details
4/5/2011$0.12$0.15ViewN/AView Earnings Details
1/4/2011$0.12$0.13ViewN/AView Earnings Details
10/7/2010Q1 2011$0.08$0.08ViewN/AView Earnings Details
7/15/2010Q4 2010$0.13$0.15ViewN/AView Earnings Details
3/31/2010Q3 2010$0.12$0.13ViewN/AView Earnings Details
1/5/2010Q2 2010$0.11$0.13ViewN/AView Earnings Details
10/6/2009Q1 2010$0.08$0.09ViewN/AView Earnings Details
7/16/2009Q4 2009$0.15$0.14ViewN/AView Earnings Details
4/2/2009Q3 2009$0.12$0.15ViewN/AView Earnings Details
1/6/2009Q2 2009$0.12$0.12ViewN/AView Earnings Details
10/2/2008Q1 2009$0.11$0.09ViewN/AView Earnings Details
7/24/2008Q4 2008$0.17$0.20ViewN/AView Earnings Details
4/2/2008Q3 2008$0.13$0.14ViewN/AView Earnings Details
1/3/2008Q2 2008$0.13$0.13ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AngioDynamics (NASDAQ:ANGO) Earnings Estimates

2018 EPS Consensus Estimate: $0.74
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.14$0.18$0.16
Q2 20182$0.15$0.16$0.16
Q3 20182$0.20$0.23$0.22
Q4 20182$0.15$0.26$0.21
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AngioDynamics (NASDAQ:ANGO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AngioDynamics (NASDAQ ANGO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 99.63%
Insider Trades by Quarter for AngioDynamics (NASDAQ:ANGO)
Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

AngioDynamics (NASDAQ ANGO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/24/2017Jan Stern ReedDirectorBuy316$16.00$5,056.00316View SEC Filing  
7/21/2017James C ClemmerCEOBuy5,000$15.79$78,950.0086,683View SEC Filing  
7/20/2017James C ClemmerCEOBuy20,000$15.64$312,800.0086,683View SEC Filing  
4/12/2017Avista Capital Partners Gp, LlMajor ShareholderSell2,350,000$16.00$37,600,000.00View SEC Filing  
8/5/2016Avista Capital Partners Gp, LlMajor ShareholderSell2,241,000$14.62$32,763,420.00View SEC Filing  
8/5/2016David F BurgstahlerDirectorSell2,250,000$14.62$32,895,000.0023,988View SEC Filing  
5/6/2016Charles R GreinerVPSell3,508$12.31$43,183.4820,910View SEC Filing  
4/25/2016Stephen A TrowbridgeSVPSell12,940$12.30$159,162.0032,469View SEC Filing  
4/14/2014Matthew KapustaSVPBuy1,000$13.90$13,900.0027,005View SEC Filing  
10/18/2013Vincent BucciDirectorBuy5,000$15.20$76,000.00View SEC Filing  
10/17/2013Howard W DonnellyDirectorSell20,000$15.06$301,200.00View SEC Filing  
7/22/2013Kevin J GouldDirectorBuy2,700$12.00$32,400.00View SEC Filing  
5/9/2013Charles R GreinerVPSell1,495$10.38$15,518.10View SEC Filing  
3/12/2013Vincent BucciDirectorBuy85,000$10.77$915,450.00View SEC Filing  
2/14/2013Vincent BucciDirectorBuy2,000$12.17$24,340.00View SEC Filing  
1/11/2013Kevin J GouldDirectorBuy2,700$11.58$31,266.00View SEC Filing  
11/5/2012Jeffrey GoldDirectorBuy1,000$10.56$10,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AngioDynamics (NASDAQ ANGO) News Headlines

Source:
DateHeadline
$86.13 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter$86.13 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - February 19 at 3:52 AM
BidaskClub Downgrades AngioDynamics (ANGO) to SellBidaskClub Downgrades AngioDynamics (ANGO) to Sell
www.americanbankingnews.com - February 17 at 11:36 PM
 Analysts Expect AngioDynamics, Inc. (ANGO) to Post $0.20 EPS Analysts Expect AngioDynamics, Inc. (ANGO) to Post $0.20 EPS
www.americanbankingnews.com - February 17 at 5:10 PM
AngioDynamics to Present at the Barclays Global Healthcare ConferenceAngioDynamics to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - February 15 at 8:39 AM
AngioDynamics, Inc. (ANGO) Given Average Rating of "Hold" by AnalystsAngioDynamics, Inc. (ANGO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 3 at 7:52 PM
$0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter$0.20 Earnings Per Share Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - January 31 at 7:14 PM
AngioDynamics (ANGO) Lowered to Hold at Zacks Investment ResearchAngioDynamics (ANGO) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 26 at 8:38 PM
AngioDynamics Receives FDA Nod, to Treat Pancreatic CancerAngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
finance.yahoo.com - January 26 at 4:20 PM
BRIEF-Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic CancerBRIEF-Angiodynamics Receives FDA Expedited Access Pathway Designation For Nanoknife System For Treatment Of Stage III Pancreatic Cancer
www.reuters.com - January 25 at 9:16 AM
AngioDynamics (ANGO) Reports FDA Expedited Access Pathway Designation for NanoKnife System for Treatment of Stage III Pancreatic CancerAngioDynamics (ANGO) Reports FDA Expedited Access Pathway Designation for NanoKnife System for Treatment of Stage III Pancreatic Cancer
www.streetinsider.com - January 25 at 9:16 AM
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic CancerAngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
finance.yahoo.com - January 24 at 4:37 PM
AngioDynamics (ANGO) Banks on Buyouts, Debt Level HighAngioDynamics (ANGO) Banks on Buyouts, Debt Level High
finance.yahoo.com - January 24 at 9:44 AM
AngioDynamics (ANGO) Upgraded to "Buy" at Zacks Investment ResearchAngioDynamics (ANGO) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 22 at 9:52 PM
AngioDynamics (ANGO) Cut to Hold at Zacks Investment ResearchAngioDynamics (ANGO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - January 19 at 7:26 PM
AngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018AngioDynamics, Inc. :ANGO-US: Earnings Analysis: Q2, 2018 By the Numbers : January 19, 2018
finance.yahoo.com - January 19 at 3:53 PM
 Analysts Expect AngioDynamics, Inc. (ANGO) Will Post Quarterly Sales of $86.13 Million Analysts Expect AngioDynamics, Inc. (ANGO) Will Post Quarterly Sales of $86.13 Million
www.americanbankingnews.com - January 16 at 5:56 AM
Zacks: Analysts Anticipate AngioDynamics, Inc. (ANGO) Will Announce Earnings of $0.19 Per ShareZacks: Analysts Anticipate AngioDynamics, Inc. (ANGO) Will Announce Earnings of $0.19 Per Share
www.americanbankingnews.com - January 14 at 7:28 PM
AngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from AnalystsAngioDynamics, Inc. (ANGO) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - January 9 at 10:22 PM
Q3 2018 EPS Estimates for AngioDynamics, Inc. (ANGO) Increased by AnalystQ3 2018 EPS Estimates for AngioDynamics, Inc. (ANGO) Increased by Analyst
www.americanbankingnews.com - January 8 at 7:12 AM
AngioDynamics (ANGO) Downgraded by BidaskClubAngioDynamics (ANGO) Downgraded by BidaskClub
www.americanbankingnews.com - January 6 at 8:52 PM
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
www.zacks.com - January 5 at 3:44 PM
Edited Transcript of ANGO earnings conference call or presentation 4-Jan-18 1:00pm GMTEdited Transcript of ANGO earnings conference call or presentation 4-Jan-18 1:00pm GMT
finance.yahoo.com - January 5 at 12:17 PM
AngioDynamics (ANGO) Downgraded to "Hold" at Craig HallumAngioDynamics (ANGO) Downgraded to "Hold" at Craig Hallum
www.americanbankingnews.com - January 5 at 7:28 AM
AngioDynamics Reports Fiscal 2018 Second Quarter Financial ResultsAngioDynamics Reports Fiscal 2018 Second Quarter Financial Results
finance.yahoo.com - January 4 at 11:10 AM
AngioDynamics misses Street 2Q forecastsAngioDynamics misses Street 2Q forecasts
finance.yahoo.com - January 4 at 11:10 AM
AngioDynamics (ANGO) Releases  Earnings ResultsAngioDynamics (ANGO) Releases Earnings Results
www.americanbankingnews.com - January 4 at 9:02 AM
AngioDynamics, Inc. (ANGO) Sees Large Growth in Short InterestAngioDynamics, Inc. (ANGO) Sees Large Growth in Short Interest
www.americanbankingnews.com - December 31 at 5:04 AM
 Brokerages Expect AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million Brokerages Expect AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million
www.americanbankingnews.com - December 30 at 2:22 AM
Zacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.17 Earnings Per ShareZacks: Brokerages Expect AngioDynamics, Inc. (ANGO) to Announce $0.17 Earnings Per Share
www.americanbankingnews.com - December 28 at 11:32 PM
ETFs with exposure to AngioDynamics, Inc. : December 28, 2017ETFs with exposure to AngioDynamics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:25 PM
AngioDynamics (ANGO) Set to Announce Earnings on ThursdayAngioDynamics (ANGO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - December 28 at 1:20 AM
AngioDynamics to Present at the J.P. Morgan Healthcare ConferenceAngioDynamics to Present at the J.P. Morgan Healthcare Conference
finance.yahoo.com - December 20 at 11:23 AM
AngioDynamics, Inc. (ANGO) Receives Consensus Recommendation of "Hold" from AnalystsAngioDynamics, Inc. (ANGO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 15 at 5:26 PM
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : December 15, 2017AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : December 15, 2017
finance.yahoo.com - December 15 at 11:50 AM
AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018
finance.yahoo.com - December 12 at 11:59 AM
$0.17 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter$0.17 EPS Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - December 11 at 7:14 PM
AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : December 5, 2017AngioDynamics, Inc. breached its 50 day moving average in a Bearish Manner : ANGO-US : December 5, 2017
finance.yahoo.com - December 5 at 12:59 PM
 Brokerages Anticipate AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million Brokerages Anticipate AngioDynamics, Inc. (ANGO) Will Announce Quarterly Sales of $87.80 Million
www.americanbankingnews.com - November 25 at 2:14 AM
AngioDynamics, Inc. – Value Analysis (NASDAQ:ANGO) : November 24, 2017AngioDynamics, Inc. – Value Analysis (NASDAQ:ANGO) : November 24, 2017
finance.yahoo.com - November 24 at 11:44 AM
Zacks: Brokerages Expect AngioDynamics, Inc. (ANGO) Will Post Earnings of $0.17 Per ShareZacks: Brokerages Expect AngioDynamics, Inc. (ANGO) Will Post Earnings of $0.17 Per Share
www.americanbankingnews.com - November 23 at 11:16 PM
AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : November 22, 2017AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : November 22, 2017
finance.yahoo.com - November 22 at 4:27 PM
AngioDynamics, Inc. (ANGO) Given Consensus Recommendation of "Hold" by BrokeragesAngioDynamics, Inc. (ANGO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 20 at 5:44 PM
$88.61 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter$88.61 Million in Sales Expected for AngioDynamics, Inc. (ANGO) This Quarter
www.americanbankingnews.com - November 6 at 2:32 AM
Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?
finance.yahoo.com - October 30 at 4:48 PM
ETFs with exposure to AngioDynamics, Inc. : October 27, 2017ETFs with exposure to AngioDynamics, Inc. : October 27, 2017
finance.yahoo.com - October 27 at 6:06 PM
AngioDynamics, Inc. (ANGO) Receives Consensus Rating of "Hold" from BrokeragesAngioDynamics, Inc. (ANGO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 26 at 9:38 PM
AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : October 17, 2017AngioDynamics, Inc. breached its 50 day moving average in a Bullish Manner : ANGO-US : October 17, 2017
finance.yahoo.com - October 17 at 4:43 PM
 Analysts Anticipate AngioDynamics, Inc. (ANGO) to Announce $0.17 Earnings Per Share Analysts Anticipate AngioDynamics, Inc. (ANGO) to Announce $0.17 Earnings Per Share
www.americanbankingnews.com - October 16 at 6:24 AM
AngioDynamics, Inc. (ANGO) Earns "Hold" Rating from Canaccord GenuityAngioDynamics, Inc. (ANGO) Earns "Hold" Rating from Canaccord Genuity
www.americanbankingnews.com - October 9 at 3:16 PM
Earnings Review and Free Research Report: Lakeland’s Revenue Jumped 7.4%; EPS Surged 25%Earnings Review and Free Research Report: Lakeland’s Revenue Jumped 7.4%; EPS Surged 25%
finance.yahoo.com - October 4 at 2:21 PM

SEC Filings

AngioDynamics (NASDAQ:ANGO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AngioDynamics (NASDAQ:ANGO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AngioDynamics (NASDAQ ANGO) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.